



## IBA Signs Contract to Install *Proteus*<sup>®</sup>*ONE* Compact Proton Therapy Center in Abu Dhabi, UAE

**Contract based on previously announced letter of intent to install  
*Proteus*<sup>®</sup>*ONE* center**

**Louvain-la-Neuve, Belgium, September 27, 2016** - IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that it has signed a contract with Proton Partners International (PPI) to install a *Proteus*<sup>®</sup>*ONE*\* compact proton therapy solution in a private clinic in Abu Dhabi, UAE.

This will be the first ever compact proton therapy solution to be sold and installed in the Middle East region.

The contract, which was previously announced upon the signing of a letter of intent in an IBA press release dated June 28<sup>th</sup> 2016, covers delivery of the *Proteus*<sup>®</sup>*ONE* equipment, including Pencil Beam Scanning (PBS) and Cone Beam CT (CBCT) capabilities, making it the compact solution best suited for Adaptive Treatment. The contract also includes a maintenance agreement. The typical end-user price for a *Proteus*<sup>®</sup>*ONE* solution with a maintenance contract is between EUR 35 and 40 million.

This project, the fourth center to be built for PPI, is part of a framework agreement that IBA and Philips signed in September 2014 to advance the diagnosis and treatment of cancer.

**Olivier Legrain, Chief Executive Officer of IBA, commented:** "Proton Partners International's partnership with IBA, born from IBA's longstanding partnership with Philips, not only strengthens our world leading position in proton therapy, but also highlights the preference of IBA as the most experienced and most reliable proton therapy provider in the market with the fastest delivery times. We are excited about our first project in the Middle East, a region that holds tremendous potential for proton therapy."

**Mike Moran, Chief Executive Officer of Proton Partners International Limited, added:** "We have been extremely satisfied with our collaboration with IBA and thus it was a natural choice to select IBA for our new project in the Middle East. We are excited about the opportunity to deliver the first proton therapy centre in Abu Dhabi, UAE and we look forward to working with a range of stakeholders to help support the research effort in the wider use of proton beam therapy for the benefit of the patients from all over Middle East region."

- Ends -



## **About Proteus®ONE**

*Proteus®ONE* is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. *Proteus®ONE* is smaller, more affordable, easier to install and to operate. It is ultimately easier to finance, making this advanced radiation therapy modality available to more institutions and patients worldwide. *Proteus®ONE* makes proton therapy easy.

\* *Proteus®ONE* is the brand name of a *Proteus®235* configuration

## **About IBA**

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)

## **About Proton Partners International Limited**

Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation's cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors have committed to almost £100m equity finance in the company.

Professor Gordon McVie, Senior Consultant at the European Institute of Oncology, has been appointed chairman, Professor Karol Sikora is Chief Medical Advisor and one of the Founders, Mike Moran has been appointed as the Chief Executive Officer. [www.proton-int.com](http://www.proton-int.com)

# Press release |

Regulated information



## For further information please contact:

### IBA

#### Investor Relations

##### **Jean-Marc Bothy**

Chief Strategy Officer

##### **Soumya Chandramouli**

Chief Financial Officer

+32 10 475 890

[Investorrelations@iba-group.com](mailto:Investorrelations@iba-group.com)

#### Media Relations

##### **Thomas Ralet**

Vice-President Corporate Communication

+32 10 475 890

[Communication@iba-group.com](mailto:Communication@iba-group.com)

## For media and investor enquiries:

### Consilium Strategic Communications

Jonathan Birt, Matthew Neal, Ivar Milligan,  
Melissa Gardiner

+44 (0) 20 3709 5700

[IBA@consilium-comms.com](mailto:IBA@consilium-comms.com)

### Rx Communications Group (US)

Melody Carey

+ 1 917 322 2571

[IBA@RxIR.com](mailto:IBA@RxIR.com)